Company / Operating Income
INOVIO PHARMACEUTICALS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$112.4M
FY2025
5-year range
-$301.2M / -$111.1M
FY2021-FY2025
Trend
+21.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$301M to -$112M over the past 2 years.
Based on SEC 10-K filings.
-$112M in FY2025.
Improved from -$301M to -$112M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 21.9% year-over-year.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$112.4M | +21.9% |
| FY2024 | -$143.9M | +52.2% |
| FY2023 | -$301.2M | -142.8% |
| FY2022 | -$124.1M | -11.7% |
| FY2021 | -$111.1M | -18.1% |
| FY2020 | -$94.1M | -12.5% |
| FY2019 | -$83.6M | -9.7% |
| FY2018 | -$76.2M | -122.4% |
| FY2017 | -$34.3M | +13.2% |
| FY2016 | -$39.5M | -102.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026